Manaolana Oncology

Executive Summary

Manaolana Oncology is a clinical-stage biotechnology company headquartered in Honolulu, Hawaii, focused on developing targeted therapies and immunotherapies for various cancers. Founded in 2017, the company operates in the oncology and immunology space and has advanced to Phase 2 clinical trials. While specific pipeline details are not publicly disclosed, the company's strategic focus on combination immunotherapies and precision oncology positions it to address significant unmet needs in solid tumors. With a lean operational structure and a founding team likely leveraging Hawaii's research ecosystem, Manaolana aims to differentiate through novel mechanisms of action. The company's progress through Phase 2 suggests it has generated early clinical data supporting further development, though validation from independent data monitors or regulatory interactions remains pending. Financially, the company is private and has not disclosed total funding, implying a reliance on private investors or grants. The key risk is the high attrition rate in oncology Phase 2 trials, but a focused approach and potential for accelerated approval could mitigate this. Overall, Manaolana represents an early-stage opportunity with significant upside if its lead candidate demonstrates efficacy and safety.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for lead asset40% success
• Q1 2027Series B financing round70% success
• Q2 2027FDA meeting to discuss Phase 3 path50% success